Common issues include gastrointestinal (GI) discomfort, such as nausea, vomiting, diarrhea, and constipation, especially in GLP-1 receptor agonists like semaglutide and liraglutide
A 2023 analysis published in JAMA Network Open found that high out-of-pocket costs for GLP-1 receptor agonists were the primary driver of treatment discontinuation within the first 12 months, with 42.1% of commercially insured patients stopping therapy by month 12
This gets back to the problem that we had in the very beginning
If youre exploring formulas in this category, the Healthy Aging Supplements collection is a natural place to begin
The post also calls proper training from the prescribing provider essential for safety
If you took a GLP-1 RA and developed a DVT, contact a Motley Rice attorney to better understand your options